참고문헌
- Nelson RH (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 40, 195-211 https://doi.org/10.1016/j.pop.2012.11.003
- Jeong SJ, Lee MN and Oh GT (2017) The Role of Macrophage Lipophagy in Reverse Cholesterol Transport. Endocrinol Metab 32, 41-46 https://doi.org/10.3803/EnM.2017.32.1.41
- Weber C and Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17, 1410-1422 https://doi.org/10.1038/nm.2538
- Hebert PR, Gaziano JM, Chan KS and Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 278, 313-321 https://doi.org/10.1001/jama.1997.03550040069040
- Pignone M, Phillips C and Mulrow C (2000) Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 321, 983-986 https://doi.org/10.1136/bmj.321.7267.983
- Cheung BM and Lam KS (2010) Is intensive LDLcholesterol lowering beneficial and safe? Lancet 376, 1622-1624 https://doi.org/10.1016/S0140-6736(10)61545-0
- Nissen SE, Tuzcu EM, Schoenhagen P et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352, 29-38 https://doi.org/10.1056/NEJMoa042000
- Davis HR Jr, Compton DS, Hoos L and Tetzloff G (2001) Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 21, 2032-2038 https://doi.org/10.1161/hq1201.100260
- Smith L, Mosley J, Yates J and Caswell L (2016) The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy. J Pharm Pharm Sci : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 19, 137-146
- Brousseau ME, Schaefer EJ, Wolfe ML et al (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350, 1505-1515 https://doi.org/10.1056/NEJMoa031766
- White CR, Datta G, Zhang Z et al (2008) HDL therapy for cardiovascular diseases: the road to HDL mimetics. Curr Atheroscler Rep 10, 405-412 https://doi.org/10.1007/s11883-008-0063-6
- Writing Group M, Mozaffarian D, Benjamin EJ et al (2016) Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 133, e38-360
- Layland J, Carrick D, Lee M, Oldroyd K and Berry C (2014) Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv 7, 581-591 https://doi.org/10.1016/j.jcin.2014.02.009
- Bowser JL, Lee JW, Yuan X and Eltzschig HK (2017) The hypoxia-adenosine link during inflammation. J Appl Physiol 123, 1303-1320 https://doi.org/10.1152/japplphysiol.00101.2017
- Sheth S, Brito R, Mukherjea D, Rybak LP and Ramkumar V (2014) Adenosine receptors: expression, function and regulation.Int J Mol Sci 15, 2024-2052 https://doi.org/10.3390/ijms15022024
- Chen JF, Eltzschig HK and Fredholm BB (2013) Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov 12, 265-286 https://doi.org/10.1038/nrd3955
- Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19, 184-191 https://doi.org/10.1016/S0165-6147(98)01203-6
- Borea PA, Varani K, Vincenzi F et al (2015) The A3 adenosine receptor: history and perspectives. Pharmacol Rev 67, 74-102
- Jeong LS, Choe SA, Gunaga P et al (2007) Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem 50, 3159-3162 https://doi.org/10.1021/jm070259t
- Lee J, Hwang I, Lee JH, Lee HW, Jeong LS and Ha H (2013) The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis. Am J Pathol 183, 1488-1497 https://doi.org/10.1016/j.ajpath.2013.07.010
- Libby P, Ridker PM and Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 https://doi.org/10.1038/nature10146
- Libby P, Schoenbeck U, Mach F, Selwyn AP and Ganz P (1998) Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med 104, 14S-18S
- Istvan ES and Deisenhofer J (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164 https://doi.org/10.1126/science.1059344
- Hou R and Goldberg AC (2009) Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety. Endocrinol Metab Clin North Am 38, 79-97 https://doi.org/10.1016/j.ecl.2008.11.007
- Lee MR, Lim CJ, Lee YH et al (2014) The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice. Nat Commun 5, 4410 https://doi.org/10.1038/ncomms5410
- Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50, 1955-1966 https://doi.org/10.1194/jlr.R900010-JLR200
- Chiang JY, Kimmel R, Weinberger C and Stroup D (2000) Farnesoid X receptor responds to bile acids and represses cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Biol Chem 275, 10918-10924 https://doi.org/10.1074/jbc.275.15.10918
- Bonovas S, Nikolopoulos G and Sitaras NM (2011) Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet 377, 715; author reply 715-716
- Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2, 517-526 https://doi.org/10.1038/nrd1112
- Pedersen TR and Tobert JA (1996) Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Drug Saf 14, 11-24 https://doi.org/10.2165/00002018-199614010-00003
- Dembowski E and Davidson MH (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16, 183-188 https://doi.org/10.1097/MED.0b013e3283295297
- Michos ED, Sibley CT, Baer JT, Blaha MJ and Blumenthal RS (2012) Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 59, 2058-2064 https://doi.org/10.1016/j.jacc.2012.01.045
- Leiva A, Guzman-Gutierrez E, Contreras-Duarte S et al (2017) Adenosine receptors: Modulators of lipid availability that are controlled by lipid levels. Mol Aspects Med 55, 26-44 https://doi.org/10.1016/j.mam.2017.01.007
- Reiss AB and Cronstein BN (2012) Regulation of foam cells by adenosine. Arterioscler Thromb Vasc Biol 32, 879-886 https://doi.org/10.1161/ATVBAHA.111.226878
- Ohisalo JJ (1981) Effects of adenosine on lipolysis in human subcutaneous fat cells. J Clin Endocrinol Metab 52, 359-363 https://doi.org/10.1210/jcem-52-2-359
- Heseltine L, Webster JM and Taylor R (1995) Adenosine effects upon insulin action on lipolysis and glucose transport in human adipocytes. Mol Cell Biochem 144, 147-151 https://doi.org/10.1007/BF00944394
- Bingham TC, Fisher EA, Parathath S, Reiss AB, Chan ES and Cronstein BN (2010) A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux.J Leukoc Biol 87, 683-690 https://doi.org/10.1189/jlb.0709513
- Jones MR, Zhao Z, Sullivan CP et al (2004) A(3) adenosine receptor deficiency does not influence atherogenesis. J Cell Biochem 92, 1034-1043 https://doi.org/10.1002/jcb.20122
- Yu J, Ahn S, Kim HJ et al (2017) Polypharmacology of N(6)-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) gamma Partial Agonist and PPARdelta Antagonist Activity Suggests Their Antidiabetic Potential. J Med Chem 60, 7459-7475 https://doi.org/10.1021/acs.jmedchem.7b00805
- Park HJ, Kim MK, Kim Y et al (2017) Gastrin-releasing peptide promotes the migration of vascular smooth muscle cells through upregulation of matrix metalloproteinase-2 and -9. BMB Rep 50, 628-633 https://doi.org/10.5483/BMBRep.2017.50.12.158
- Jung HJ, Im SS, Song DK, Bae JH (2017) ffects of chlorogenic acid on intracellular calcium regulation in lysophosphatidylcholine-treated endothelial cells. BMB Rep 50, 323-328 https://doi.org/10.5483/BMBRep.2017.50.6.182